Carles Bofill-Bonet

Carles Bofill-Bonet

Auto-generated profile, based on publicly available information

Carles Bofill-Bonet

Institut Químic de Sarrià (IQS), Universitat Ramon Llull (URL), Via Augusta 390, 08017, Barcelona, Spain

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 September 2023 in Journal of Molecular Liquids
Verified
Journal Article
Closed access
CBCarles Bofill-Bonet
Carles Bofill-Bonet
MGMaria Gil-Vives
Maria Gil-Vives
MAMargalida Artigues-Cladera
Margalida Artigues-Cladera
MHMarta Hernández
Marta Hernández
SBSalvador Borros
Salvador Borros
Cristina FornagueraCristina Fornaguera
Cristina Fornaguera

20 January 2026 in Drug Delivery and Translational Research
Verified
Journal Article
Open access
PDF file
CBCarles Bofill-Bonet
Carles Bofill-Bonet
GFGermán Febas
Germán Febas
MAMargalida Artigues-Cladera
Margalida Artigues-Cladera
IMInés Moreno-Jiménez
Inés Moreno-Jiménez
NBNoemí Balà
Noemí Balà
Cristina FornagueraCristina Fornaguera
Cristina Fornaguera
Doxycycline (DOXY) is a well-established antibiotic that has recently shown potential in inhibiting matrix metalloproteinase-2 (MMP-2), a key enzyme involved in the progression of abdominal aortic aneurysms (AAA). However, the controlled delivery of DOXY to the aneurysm site, with sustained release and minimal systemic exposure, remains a critical challenge in therapeutic development. To address this, we developed a targeted drug delivery platform based on polymeric nanoparticles (NPs), prepared from water-in-oil-in-water nano-emulsions, encapsulating DOXY and are covalently attached to electrospun ε-poly(caprolactone) (ε-PCL) microfibers. This system was designed to enable local, sustained drug release in the inner wall of aorta while preserving the mechanical properties of the aortic wall. The ε-PCL electrospun microfibers from the patch were first functionalized using oxygen cold plasma treatment, creating free radicals that enabled covalent bonding with chemical groups on the outer layer of DOXY-loaded poly(lactic-co-glycolic acid) (PLGA) NPs. This strategy allowed for robust immobilization of the NPs onto the microfibers surface, forming a composite system capable of localized and controlled drug release over time. Unlike traditional delivery approaches, this method ensures site-specific action of DOXY directly at the aneurysmal tissue, minimizing systemic circulation and reducing off-target toxicity. The platform not only provides a stable drug reservoir but also offers intrinsic biomechanical reinforcement, which is critical in AAA condition. This innovative delivery system represents a significant advance in the localized treatment of vascular disorders. It offers a biocompatible, biodegradable, and precisely targeted therapeutic approach, with potential to reduce the need for surgical intervention and limits the adverse effects associated with systemic drug administration. Highlights: - Novel polymeric Doxycycline loaded PLGA nanoparticles have been developed and result efficacious within hMMP-2 mitigation and collagen degradation in Abdominal Aortic Aneurysm condition. - Doxycycline loaded polymeric nanoparticles were covalently anchored to ε-Poly(caprolactone) electrospun microfibers via cold plasma-induced radical grafting, enabling sustained drug release for over 12 days. - Doxycycline-loaded nanoparticles released from microfibers efficaciously mitigate hMMP-2 in human in vitro models of Abdominal Aortic Aneurysm. - Doxycycline released from drug-coated electrospun ε-Poly(caprolactone) although efficacious does not allows time-control.

31 March 2026 in Talanta
Verified
Journal Article
Open access
CBCarles Bofill-Bonet
Carles Bofill-Bonet
MAMargalida Artigues-Cladera
Margalida Artigues-Cladera
IMInés Moreno-Jiménez
Inés Moreno-Jiménez
NBNoemí Balà
Noemí Balà
JMJordi Martorell
Jordi Martorell
SBSalvador Borros
Salvador Borros
Doxycycline (DOX) is a second-generation tetracycline antibiotic extensively used in clinical practice, not only for its antimicrobial activity but also for its emerging therapeutic potential in modulating extracellular matrix (ECM) in remodeling processes. Increasing evidence supports its role in attenuating pathological conditions associated with ECM degradation by targeting matrix metalloproteinases type 2 (MMP-2), including cancer progression and abdominal aortic aneurysm (AAA). However, DOX exhibits limited stability in aqueous and semi-physiological environments, undergoing hydrolysis and oxidative reactions that lead to the generation of multiple degradation byproducts, thereby compromising its efficacy and safety profile. In this study, we systematically mapped the degradation pathways of DOX under rigorously controlled physicochemical and biological conditions. High-resolution QTOF mass spectrometry operating in SWATH data-independent acquisition mode enabled unbiased identification of multiple, structurally distinct degradation byproducts, as well as the DOX parent compound, using curated metabolite libraries from SCIEX platform. Building on this annotation step, we established a complementary QTrap-based targeted workflow to quantify low-abundance metabolites intra- and extracellular through isotope-specific transitions derived from the QTOF analysis and to monitor their temporal kinetics with high sensitivity. Together, this integrated analytical strategy provides refined insight into the intrinsic instability of DOX and its potential biological consequences. To translate degradation mapping into a biologically relevant context, OM-PLGA NPs were incorporated as a controlled delivery platform that modulates DOX exposure, slows spontaneous degradation, and creates the matrix conditions required to validate the sensitivity of the QTRAP workflow in complex cellular environments. This validation demonstrated that OM-PLGA nanoparticles not only preserve DOX in its bioactive form through microenvironmental shielding, but also results in enhanced pharmacological activity, particularly sustained inhibition of MMP-2, a central enzyme in AAA-associated ECM remodeling. Together, these results highlight the dual value of the advanced analytical workflow and the nanocarrier strategy, demonstrating how integrating high-resolution mass spectrometry with nanoparticle engineering overcomes the intrinsic instability of DOX and provides deeper mechanistic insight across both analytical and biological dimensions.